

#5



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets



Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00306613.1



**R.C. VAN DIJK**

Der Präsident des Europäischen Patentamts;  
im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**I.L.C. HATTEN-HECKMAN**

DEN HAAG, DEN  
THE HAGUE, 22/08/01  
LA HAYE, LE





Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der B sch inigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.:  
Demande n°: 00306613.1

Anmeldetag:  
Date of filing: 03/08/00  
Date de dépôt:

Anmelder:  
Applicant(s):  
Demandeur(s):  
UNILEVER PLC  
London EC4P 4BQ  
UNITED KINGDOM

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:  
Peptides capable of functioning as mimotopes for estradiol analytes

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:	Tag:	Aktenzeichen:
State:	Date:	File no.
Pays:	Date:	Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:  
C07K5/08, C07K5/10, C07K7/06, C07K1/04, A61K31/365, G01N33/53

Am Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:

See for original title of the application page 1 of the description



- 1 -

Peptides Capable of Functioning as Mimotopes for Hormonal AnalytesField of the Invention

5

This invention relates to the discovery that certain peptide molecules have similar reactive properties as certain steroidal compounds, notwithstanding the significant structural dissimilarities between such compounds, and are thus capable of functioning as mimotopes of the steroidal compounds in, for example, displacement immunoassays designed for the detection of steroids.

10

Background of the Invention

15

As a matter of general definition, an epitope is that region of a particular antigen which contains the critical binding region of the antigen necessary for triggering an immunity-related antibody binding response. Epitopes are also often referred to in the alternative as antigenic determinants.


20

Understanding the structures of epitopes as well as their specific binding reactions to particular antibodies is of significant interest to many, as such an understanding could lay the foundation for advancements in the pharmaceutical, diagnostic and health industries. To facilitate this understanding, in recent years academic institutions and industry have constructed what are termed epitope libraries.

25

Epitope libraries are large collections of variable amino acid sequences that are displayed, for example, on the surfaces of bacteriophage. Each sequence corresponds to a particular epitope of a particular antigen. Often, the epitope libraries will consist of many millions of these short amino acid sequences, sometimes even

30



- 3 -

the binding cleft of the antibody directed to the antigen containing the particular epitope.

Though mimotopes technically can be any molecules or sequence of molecules which mimic an epitope, they are most often small, low molecular weight peptides which comprise short sequences of amino acids. Because they are most typically small peptides, they have been thought to be constrained in what they can mimic. Specifically, it has been a generally held belief that peptide mimotopes could be identified for numerous protein based antigens (i.e. those antigens with peptide epitopes), but that because of the complex structure of antibody binding clefts, and the correspondingly complex nature of the antibody binding response, all of which it was believed would require a close similarity in structure between the mimotope and epitope in order for mimotope-antibody binding to occur, the identification of peptide mimotopes for non-protein based antigens would be difficult to achieve.

In *Random peptide libraries: A source of specific binding molecules*: Devlin JJ: Science 249, 404-406 (1990), peptide mimotopes have been identified for biotin, an essential vitamin necessary for certain enzymatic carboxylation reactions in living cells. Though biotin is not peptidal in structure, it is nevertheless similar in size and structure to several amino acids (for example, histidine). Thus, it was not unexpected that a peptide mimotope for such a molecule could be identified.

Similarly, in *Peptide ligands for a sugar binding protein isolated from a random peptide library*: Oldenburg, KR et al., Proc. Nat. Acad. Sci. USA, 89, 5393-5397 (1992), peptide mimotopes for the mannopyranoside ligand of concanavalin A have been identified. Again though, such mimotopes are of similar size and have a similar structural configuration to the epitopes which they mimic and thus their identification was less than surprising. Mimotopes of certain





- 5 -

Further, they can be bound directly to certain assay surfaces which are otherwise non-compatible with estradiol, the estradiol on such surfaces needing to be bound to the surface by complexing with another -- often proteinaceous - molecule. Other advantages will  
5 become readily apparent in the description of the invention below.

#### Detailed Description of the Invention

The peptide mimotopes of the invention are capable of specific  
10 binding to any antibody which is specific to estradiol. Estradiol as used herein shall be taken to mean estradiol or metabolites thereof (e.g. the preferred estrone-3-glucuronide), as well as any related steroidal compounds having a basic estrone structure. Such related compounds are exemplified by estriol, 16-epiestriol, 17-  
15 epiestriol, 17- $\beta$ -estradiol 3-( $\beta$ -D-glucuronide), estriol 3-( $\beta$ -D-glucuronide), estrone, 17  $\alpha$ -ethynylestradiol, and 16  $\alpha$ -hydroxyestrone.

By specific binding it is meant that the mimotope is capable of  
20 being bound to an antibody in a selective fashion in the presence of excess quantities of other materials not of interest, and tightly enough (i.e. with high enough affinity) that when used in an immunoassay, it provides a useful assay result.

25 The antibody to which the peptide mimotopes are capable of being specifically bound can be any antibody, fragment or construct thereof, having a binding specificity for estradiol or metabolites thereof. Various forms of such antibodies are contemplated which may include monoclonal or polyclonal antibodies, Fv, Fab,  
30 ScFv and the like. Also contemplated are multivalent and/or multispecific constructions which have been described in the literature and comprise two or more polypeptide chains -- see for example, patent application Harris et al., WO 94/09131 and Davis et al., WO 97/14719 -- or are based on a 'double ScFv'



- 7 -

The peptide mimotopes can be any size, though it is preferable that they be smaller than that which would allow for tertiary or globular structuring to occur. Thus, they are typically no larger than 30, and preferably no greater than 20, amino acids in length. The core binding region of each mimotope will typically be less than 12 amino acids, preferably less than 7 amino acids, and optimally between 3 to 6 amino acids in length.

Purification of the peptide mimotopes can be accomplished by conventional means, such as those described in Tendler et al., *The role of the arginine residue in the stabilization of mucin core type 1  $\beta$  turns*. Protein and Peptide Letters, 1, 39-43 (1994). Preferably, the peptide mimotopes will be purified to 95%, optimally to 99%.

In one embodiment of the invention, the peptide mimotopes are utilized in an immunoassay test device. Such a device can take different forms, and it can be varied depending on the precise nature of the assay being performed.

Because the peptide mimotopes "mimic" a substance (i.e. Estradiol) which will often be the subject of testing, they are essentially antigenic by nature and function. Thus, it is most preferable that they be utilized in competitive or displacement-type assays (hereinafter collectively referred to as competitive assays). Nothing, however, would preclude their usage in conventional sandwich-type assays as well and specific formats can be readily designed.

Specifically, it is contemplated that in a competitive assay incorporating the peptide mimotopes of the invention, the mimotopes would be coated onto a solid support, typically nitrocellulose or other hydrophobic porous material. They may also be coated on synthetic plastics materials, microtitre assay plates, latex beads,

03-08-2000



- 9 -

measurable signal of the amount of peptide mimotopes displaced and hence the amount of estradiol in the sample.

Other immunoassay test devices contemplated by the invention  
5 include those employing, for example, capillary-fill means in which a liquid sample is drawn into a device by capillary action along a suitably-proportioned capillary inlet. Capillary-fill devices which may be adapted for use in the present invention are disclosed, for example, in Shanks et al., U.S. Patent 5,141,868, Shanks et al.,  
10 EP-A-0422708, and Birch et al., EP-B-0274215.

Devices such as those described in May et al., U.S. Patent 5,622,871 and May et al., U.S. Patent 5,656,503 are also suitable for practice of the immunoassays of the invention. If used, these  
15 devices preferably comprise a hollow elongated casing containing the solid support. The solid support communicates indirectly with the exterior of the casing via a bibulous fluid sample receiving member which may or may not protrude from the casing, the solid support and the sample receiving member being linked so as to allow  
20 for the fluid sample to migrate between the two by capillary action.

Spatially distant along the solid support from the sample receiving member are the test and, optionally, control zones. Within the test  
25 zone, the peptide mimotopes can be bound to an antibody immobilized on the support. Such immobilisation can be accomplished by any number of known means including chemically coupling using, for example, CNBr, carbonyldiimidazole, or tresyl chloride. Alternatively, various "printing" techniques may be used. These  
30 include application of liquid antibodies by micro-syringes, direct printing, ink-jet printing, and the like. Chemical or physical treatment of the support prior to application of the antibody is also specifically contemplated, as such may facilitate immobilisation.

- 10 -

The casing in such devices is typically constructed of opaque or translucent material incorporating at least one aperture through which the analytical result may be observed, either by the naked eye or electronic means.

5

Such devices can be provided to clinical laboratories or as kits suitable for home use, such kits comprising one or more devices individually wrapped in moisture impervious wrapping and packaged together with appropriate instructions to the user.

10

The sample receiving member can be made from any bibulous, porous or fibrous material capable of absorbing liquid rapidly. The porosity of the material can be unidirectional (i.e. with pores or fibres running wholly or predominantly parallel to an axis of the member) or multidirectional (omnidirectional, so that the member has an amorphous sponge-like structure). Porous plastics material, such as polypropylene, polyethylene (preferably of very high molecular weight), polyvinylidene fluoride, ethylene vinylacetate, acrylonitrile and polytetrafluoro-ethylene can be used. It can be advantageous to pre-treat the member with a surface-active agent during manufacture, as this can reduce any inherent hydrophobicity in the member and therefore enhance its ability to take up and deliver a moist sample rapidly and efficiently. Porous sample receiving members can also be made from paper or other cellulosic materials, such as nitrocellulose. Preferably the material comprising the sample receiving member should be chosen such that the porous member can be saturated with liquid sample within a matter of seconds. The liquid must be capable of permeating freely from the porous sample receiving member into the solid support.

30

The solid support in such devices is preferably a dry porous carrier. It may be made of separate strips or sheets and, like the sample receiving member, can be constructed from any material capable of allowing the liquid sample to migrate through a portion

- 11 -

of its length by, preferably, capillary action. The support should allow for the immobilisation of the antibody and/or peptide mimotope on its surface, and should not interfere with the binding reactions which are necessary for the proper functioning of the  
5 assay.

The solid support may have associated with it an absorbent "sink" which will facilitate capillary action of fluid up the length of the support, and will provide a means by which to avoid flooding of  
10 the test device by application of excess sample. Specific materials for and applications of sinks are conventional in the art and may be readily applied to the devices of the present invention.

In the immunoassay test devices of the invention, in order to  
15 provide a measurable signal of the amount of analyte in the sample, it is preferred that either the peptide mimotope or the antibody to which it is bound be labelled. In the preferred embodiment of the invention, the label is any entity the presence of which can be readily detected. Preferably the label is a direct label, such as  
20 the those described in detail in May et al., U.S. Patent 5,656,503. Direct labels are entities which, in their natural state, are readily visible either to the naked eye, or with the aid of an optical filter and/or applied stimulation, e.g. UV light to promote fluorescence. Examples include radioactive, chemiluminescent,  
25 electroactive (such as redox labels), and fluorescent compounds. Direct particulate labels, such as dye sols, metallic sols (e.g. gold) and coloured latex particles, are also very suitable and are, along with fluorescent compounds, preferred. Of these options, coloured latex particles and fluorescent compounds are most  
30 preferred. Concentration of the label into a small zone or volume should give rise to a readily detectable signal, e.g. a strongly coloured area.

- 12 -

Indirect labels, such as enzymes, e.g. alkaline phosphatase and horseradish peroxidase, can also be used, but these usually require the addition of one or more developing reagents such as substrates before a visible signal can be detected. Hence, they are less preferred. Such additional reagents can be incorporated in the solid support of the assay device such that they dissolve or disperse when a liquid sample is applied. Alternatively, the developing reagents can be added to the sample before application of the sample to the solid support.

Conjugation of the label to the peptide mimotope or the antibody can be by covalent or non-covalent (including hydrophobic) bonding, or by adsorption. Techniques for such conjugation are commonplace in the art and may be readily adapted for the particular reagents employed. In the preferred embodiment wherein the label is a coloured latex particle, the label is preferably conjugated to the antibody and it is accomplished through adsorption. Where the label is a fluorescent compound, it is preferred that the label be conjugated to or constructed as part of the antibody.

Upon usage of the test device, the label can provide a test and/or control signal which can be detected from the test and control surfaces by known conventional means. This includes evaluation by the naked eye, or more typically when precise measurements are desired, by appropriate instrumentation. Instrumentation is particularly suitable when the control or test signal is measured by the amount of mass of complex at the control or test surface. The immunoassay test devices of the invention may be applied to virtually any type of biological or non-biological sample, though liquid biological samples derived from urine or serum are preferred. The samples may be purified or diluted prior to assaying.



- 13 -

The practice of the invention is described in detail below with reference to specific illustrative example, but the invention is not to be construed as being limited thereto.

5

**EXAMPLES****Identification of Peptide Mimotopes for Estradiol**

- 10 Means by which to identify examples of peptide mimotopes of the estradiol metabolite, estrone-3-glucuronide, are described below.

Monoclonal antibodies MAb 4155 were expressed from the 4155 monoclonal cell line. The 4155 monoclonal cell line was prepared  
15 and screened according to the methods described by Gani et al., (J Steroid Biochem. Molec. Biol. 48, 277-282 (1994)). The Gani et al. publication relates to development of anti-progesterone antibodies, but similar techniques were employed in producing antibodies reacting with estrone and analogues thereof.

- 20 Comparative amino acid sequences utilized in the following examples are as follows:

	Glu-Asp	(SEQ ID NO:70)
25	Ala-Ala-Glu-Arg-Gly-Leu-Phe-Glu	(SEQ ID NO:71)
	Ala-Ala-Glu-Arg-Gly-Leu-Phe	(SEQ ID NO:72)
	Ala-Ala-Glu-Arg-Gly-Leu	(SEQ ID NO:73)
	Ala-Ala-Glu-Arg-Gly	(SEQ ID NO:74)
	Ala-Ala-Glu-Arg	(SEQ ID NO:75)
30	Ala-Ala-Glu	(SEQ ID NO:76)
	Ala-Ala	(SEQ ID NO:77)
	Ala-Ala-Glu-Arg-Gly-Leu-Ala-Glu-Asp	(SEQ ID NO:78)
	Ala-Ala-Glu-Arg-Gly-Leu-Phe-Ala-Asp	(SEQ ID NO:79)
	Ala-Ala-Glu-Arg-Gly-Leu-Phe-Glu-Ala	(SEQ ID NO:80)

- 14 -

**EXAMPLE 1****Identification of Peptide Mimotope Sequences by Phage Display**

## 5 pVIII9aa-cys nonapeptide phage library

The VIII9aa-cys library phage library described by Felici F et al., *Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognised by a protective monoclonal*  
10 *antibody against the Bordetella pertussis toxin from phage peptide libraries.* Gene 128, 21-27 (1993) and Luzzago et al. *Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained*  
15 *peptides.* Gene 128, 51-57 (1993) was used. The library consisted of random nonapeptides fused to the major coat protein pVIII so that several hundred peptides were displayed on each phage particle.

## Screening of phage library

20 Affinity selection of phage was performed by a combination of the methods of Folgori A. et al. *A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera.* EMBO J 13, 2236-2243 (1994) and Parmley S.F. et al. *Antibody-selectable fd phage vectors:affinity*  
25 *purification of target genes.* Gene 73, 305-318 (1988).

Polystyrene tubes used for panning (Immunotubes™ from Nunc) were coated either with affinity-purified anti-estrone-3-glucuronide antibodies (20 µg) in 2 mls of coating buffer (0.1 M NaHCO<sub>3</sub>, pH 9.0) or with coating buffer only overnight at 4° C. After three  
30 washes with tris buffered saline (TBS; 50 mM tris-HCl, 140 mM NaCl, pH 7.4) both tubes were incubated with 4 mls of blocking buffer (TBS containing 10 mg/ml ovalbumin) for 4 h at room temperature. The VIII9aa-cys library was shown to have a titre of  $1 \times 10^{13}$  transducing units/ml (TU/ml) by infection of logarithmic XL1-Blue

- 15 -

bacteria (Stratagene, Amsterdam, Holland). Aliquots (1  $\mu$ l;  $1 \times 10^{11}$  TU) from the donated phage suspension were added to the antibody-coated and un-coated polystyrene tubes each containing 1 ml of TBS and 1mg/ml ovalbumin and incubated overnight at 4°C. Unbound phage were removed by 15 washes (each of 4 ml) with TBS containing 0.5% (v/v) Tween 20™ (TTBS) followed by 5 washes with TBS at room temperature. Bound phage were eluted by incubation of washed panning tubes with 1ml of elution buffer (0.1 M HCl, pH 2.2, adjusted with glycine, containing 1 mg/ml ovalbumin) for 12 min at room temperature. The eluted phage were transferred to 1 ml polypropylene tubes and neutralised with 60  $\mu$ l of 2 M tris (pH not adjusted). Aliquots (200  $\mu$ l) of 1 M tris-HCl, pH 7.4 were also added to the panning tubes for neutralisation. The eluted neutralised phage particles (1 ml) were used for infection of 9 ml of logarithmic XL1-Blue bacteria (in 2TY containing 1% (w/v) glucose). Logarithmic XL1-Blue bacteria (4 ml) were also added directly to the neutralised panning tubes. Infection was carried out for 30 min at 37°C with no shaking. The infected bacteria were then pooled (total volume 13 ml) ampicillin was added (to 100 $\mu$ g/ml) and the cultures incubated overnight with shaking at 37°C. A small aliquot (10 $\mu$ l) of infected bacterial cells was removed prior to overnight incubation for titration (diluted  $10^{-2}$  to  $10^{-6}$  in 2TY/Amp/Glucose) on 2TY agar containing 1% (w/v) glucose and ampicillin (100 $\mu$ g/ml). An aliquot (150  $\mu$ l) of the overnight XL1-Blue culture infected with phage eluted from the panning tube coated with MAb 4155 antibodies was then added to 15 ml of 2TY containing 1% (w/v) glucose and 100 $\mu$ g/ml ampicillin and grown to logarithmic phase. The cells were then superinfected with M13K07 helper phage (Gibco BRL Life Technologies, Paisley, Scotland) ( $1 \times 10^{11}$  phage/ml) and incubated for 30 min without shaking at 37°C. This was followed by centrifugation for 20 min at 1800 rpm and resuspension of the cell pellet in 200 ml of 2TY containing 100 $\mu$ g/ml ampicillin and 25  $\mu$ g/ml kanamycin. The bacterial culture was then incubated overnight at 37°C with shaking. Bacterial cells

- 16 -

were then pelleted by centrifugation (5000 rpm; 15 min) and the phage particles in the supernatant precipitated by addition of 40 mls of PEG/NaCl (2.5M NaCl containing 20% (w/v) polyethylene glycol 8000) and incubation on ice for 1 hour. The phage suspension was  
5 then spun at 10,000rpm for 20 min at 4°C and the resulting pellet resuspended in 20 ml of TBS. A further PEG precipitation was carried out by addition of 4 ml of PEG/NaCl and incubation on ice for a further 20 min. The final phage pellet was dissolved in 2 ml of TBS which resulted in phage titres of the order of  $1 \times 10^{13}$   
10 TU/ml. These phage particles were added directly to fresh panning tubes and the entire panning procedure repeated a further two times. The entire screening protocol (three rounds of panning) was repeated after the first screen.

15

#### Phage ELISAs

The output from the third round of panning was plated out on 2TY agar, ampicillin (100 µg/ml) and 1% (w/v) glucose and incubated  
20 overnight at 37°C. Random individual bacterial colonies (~200) were picked and added to the wells of 96-well microtitre plates (Sterilin™) each containing 200 µl of 2TY, 1% (w/v) glucose and ampicillin (100 µg/ml). The microtitre plates were incubated overnight with shaking at 37°C. The following day aliquots from each  
25 well (20 µl) were added to the wells of fresh micotitre plates each containing 200 µl of 2TY, 1% glucose, 100 µg/ml ampicillin and incubated with shaking for 1 h at 37°C. At the next stage, 25 µl of 2TY containing ampicillin (100 µg/ml), 1% (w/v) glucose and  $10^9$  M13KO7 helper phage were added to each well. The plates were  
30 incubated for 30 min at 37°C without shaking followed by a further incubation for 1 h at 37°C with shaking. The plates were then spun at 1800 rpm for 20 min at room temperature, the supernatant aspirated off and the cell pellet resuspended in 200 µl of 2TY

- 17 -

containing ampicillin (100 µg/ml) and kanamycin (20 µg/ml). Incubation with shaking at 37°C was then carried out overnight. Centrifugation of overnight cultures in the wells of microtitre plates was carried out (1500 rpm; 20 mins) and phage-containing supernatants (100 µl) were added to sheep anti-M13 bacteriophage (C.P. Laboratories, Bishops Stortford, UK) coated microtitre plates (Greiner™, high bind). Purified sheep anti-M13 antibody-coated plates were prepared by overnight incubation (100 µl/well; 10 µg/ml) at 4°C in binding buffer (0.1 M NaHCO<sub>3</sub>, pH 9.0). Blocking was carried out with PBST containing 10 mg/ml ovalbumin (200 µl/well) for 1 h at room temperature. After removal of unbound phage from sheep anti-M13-coated plates by five washes with PBST affinity-purified anti-estrone-3-glucuronide antibodies were added (20 µg) in 2 mls of PBST containing 10 mg/ml ovalbumin; 100 µl per well). Incubation was carried out for 2 h at room temperature. Alkaline phosphatase conjugated rabbit anti-mouse immunoglobulin (100 µl/well) was then added at a dilution of 1/1000 (in PBST, 10 mg/ml ovalbumin) and incubated for a further 2 h at room temperature. The assay was developed with 100 µl/well of *p*-nitrophenyl phosphate (1 mg/ml) in 1M diethanolamine, 1 mM MgCl<sub>2</sub>, pH 9.6 and the plates read at 410 nm.

#### DNA Sequencing

Double-stranded phagemid DNA was purified from bacterial cultures (50 ml) infected with positive phage clones using the Qiagen™ plasmid purification kit according to the manufacturer's instructions. Sequencing was carried out on an Applied Biosystems automated sequencer (Model 373A, version 1.2.0) using the oligonucleotide primer SEQ ID NO 1:

5'- TTT CCC AGT CAC GAC GTT G -3'

(SEQ ID NO:1).

- 18 -

From the Phage ELISA and DNA sequencing results the following three peptide mimotope sequences were identified:

	Ala-Ala-Glu-Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:2).
5	Thr-Ala-Trp-Thr-Tyr-Val-Leu-Gly-Phe	(SEQ ID NO:3).
	Thr-Ser-Trp-Ala-Tyr-Val-Leu-Gly-Pro	(SEQ ID NO:4).

**Identification of Mimotope Core Binding Regions by Replacement Net Analysis.**

10

**Solid Phase Peptide Synthesis on Pins**

Peptides were synthesised in duplicate or triplicate from the C-terminus by solid phase peptide synthesis on the heads of  
15 polyethylene pins (Geysen et al., *Strategies for epitope analysis using peptide synthesis*. J. Immunol. Methods 102, 259-274 (1987)) using a Multipin Peptide Synthesis Kit (Chiron Mimotopes, Victoria, Australia). Pins were arranged in a plastic holder in the format of a 96-well microtitre plate.

20

**ELISA Testing of Peptides on Pins**

All incubation steps were performed at room temperature (18-25°C) by lowering the pins reagents dispensed into 96-well microtitre  
25 plates (Becton Dickinson, CA, USA). Washing was accomplished by placing the block of pins in a bath of phosphate buffered saline (PBS) containing Tween 20™ (0.01% v/v) with agitation for four cycles of 5 min. Non-specific binding sites on the surface of the pins were blocked by incubating in PBS containing casein (1% w/v,  
30 175 µl/well) for 1 h. MAb4155 was diluted in blocking buffer and the pins were incubated in the antibody solution (150 µl/well) for 18 h at 4°C. After washing, the pins were incubated in horseradish peroxidase (HRP)-conjugated rabbit anti-mouse immunoglobulin (Dako, High Wycombe, UK, 1/1000 in blocking buffer for 1 h at 150

- 19 -

5     µl/well). The pins were washed once more and then incubated in  
ABTS [2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)]  
working substrate for 15 min (150 µl/well). ABTS was prepared as a  
0.033% (w/v) solution in 0.1M citrate phosphate buffer (pH 4.5)  
with 33% hydrogen peroxide (1 µl/ml). Colour development was  
terminated by removal of the pins from the wells and was measured  
spectrophotometrically at 405 nm using a Milenia Kinetic Analyser™  
(DPC, Llanberis, Wales).

#### 10    Identification of the Core Binding Regions

15    In order to identify core binding regions, a set of peptides was  
synthesised on the heads of pins based on SEQ ID NO:2. These  
included peptides sequentially reduced in length by one amino acid,  
first from the N-terminus and then, in another series, from the C-  
terminus. In addition, a set of peptides was synthesised in which  
each residue of the lead sequence was replaced by Ala (or Gly if  
Ala already existed at that position) in order to assess the  
contribution of each residue to the binding event. MAb4155 was  
20    tested for reactivity with these peptides, the results being shown  
below in Table 1.

- 20 -

Table 1

Mimotope	SEQ ID NO:	Type	Relative Binding*
Ala-Ala-Glu-Arg-Gly-Leu-Phe-Glu-Asp	2	invention	2.0
Ala-Glu-Arg-Gly-Leu-Phe-Glu-Asp	10	invention	1.5
Glu-Arg-Gly-Leu-Phe-Glu-Asp	9	invention	1.8
Arg-Gly-Leu-Phe-Glu-Asp	8	invention	1.6
Gly-Leu-Phe-Glu-Asp	7	invention	2.2
Leu-Phe-Glu-Asp	6	invention	1.9
Phe-Glu-Asp	5	invention	2.0
Glu-Asp	4	comparison	1.0
Ala-Ala-Glu-Arg-Gly-Leu-Phe-Glu	71	comparison	1.0
Ala-Ala-Glu-Arg-Gly-Leu-Phe	72	comparison	1.0
Ala-Ala-Glu-Arg-Gly-Leu	73	comparison	1.0
Ala-Ala-Glu-Arg-Gly	74	comparison	1.0
Ala-Ala-Glu-Arg	75	comparison	0.8
Ala-Ala-Glu	76	comparison	0.9
Ala-Ala	77	comparison	1.0
Gly-Ala-Glu-Arg-Gly-Leu-Phe-Glu-Asp	11	invention	1.9
Ala-Gly-Glu-Arg-Gly-Leu-Phe-Glu-Asp	12	invention	2.0
Ala-Ala-Ala-Arg-Gly-Leu-Phe-Glu-Asp	13	invention	1.5
Ala-Ala-Glu-Ala-Gly-Leu-Phe-Glu-Asp	14	invention	2.0
Ala-Ala-Glu-Arg-Ala-Leu-Phe-Glu-Asp	15	invention	1.5
Ala-Ala-Glu-Arg-Gly-Ala-Phe-Glu-Asp	16	invention	1.6
Ala-Ala-Glu-Arg-Gly-Leu-Ala-Glu-Asp	78	comparison	0.8
Ala-Ala-Glu-Arg-Gly-Leu-Phe-Ala-Asp	79	comparison	1.8
Ala-Ala-Glu-Arg-Gly-Leu-Phe-Glu-Ala	80	comparison	1.1

5 \* Relative Binding of MAb4155 to peptides as measured by ELISA as described above

As is demonstrated from the data, only those amino acid sequences comprising the core binding region as indicated by SEQ ID NO:5  
 10 provided adequate binding. Amino acid sequences represented by SEQ ID NO:6 - 16 contain the core binding region of SEQ ID NO:5 and provided adequate binding to serve as an estradiol mimotope.

	Phe-Glu-Asp	(SEQ ID NO:5)
15	Leu-Phe-Glu-Asp	(SEQ ID NO:6)
	Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:7)
	Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:8)
	Glu-Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:9)
	Ala-Glu-Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:10)



- 21 -

	Gly-Ala-Glu-Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:11)
	Ala-Gly-Glu-Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:12)
	Ala-Ala-Ala-Arg-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:13)
	Ala-Ala-Glu-Ala-Gly-Leu-Phe-Glu-Asp	(SEQ ID NO:14)
5	Ala-Ala-Glu-Arg-Ala-Leu-Phe-Glu-Asp	(SEQ ID NO:15)
	Ala-Ala-Glu-Arg-Gly-Ala-Phe-Glu-Asp	(SEQ ID NO:16)

Additional core binding sequences were identified utilizing the amino acid sequence SEQ ID NO:7 and investigating the effect of systematic replacement of each residue by the other 19 naturally occurring amino acids using known techniques as exemplified in Verhoeyen et al., *Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody*. Immunology, 78, 364-370 (1993).

The sequences which had superior binding reactivity and specificity compared to SEQ ID NO:7 are identified as follows. The binding of MAb4155 to these sequences as determined by ELISA is shown below in Table 2, setting SEQ ID NO:7 to a Relative Binding of 100.

20	Gly-Phe-Phe-Glu-Asp	(SEQ ID NO:17)
	Gly-Trp-Phe-Glu-Asp	(SEQ ID NO:18)
	Gly-Tyr-Phe-Glu-Asp	(SEQ ID NO:19)
	Gly-Leu-Trp-Glu-Asp	(SEQ ID NO:20)
25	Gly-Leu-Phe-Cys-Asp	(SEQ ID NO:21)
	Gly-Leu-Phe-Asp-Asp	(SEQ ID NO:22)
	Gly-Leu-Phe-Phe-Asp	(SEQ ID NO:23)
	Gly-Leu-Phe-Ile-Asp	(SEQ ID NO:24)
	Gly-Leu-Phe-Leu-Asp	(SEQ ID NO:25)
30	Gly-Leu-Phe-Trp-Asp	(SEQ ID NO:26)
	Gly-Leu-Phe-Tyr-Asp	(SEQ ID NO:27)
	Gly-Leu-Phe-Glu-Cys	(SEQ ID NO:28)
	Gly-Leu-Phe-Glu-Phe	(SEQ ID NO:29)
	Gly-Leu-Phe-Glu-Ile	(SEQ ID NO:30)

- 22 -

Gly-Leu-Phe-Glu-Leu (SEQ ID NO:31)  
 Gly-Leu-Phe-Glu-Val (SEQ ID NO:32)  
 Gly-Leu-Phe-Glu-Trp (SEQ ID NO:33)  
 Gly-Leu-Phe-Glu-Tyr (SEQ ID NO:34)

5

**Table 2**

Mimotope	SEQ ID NO:	Relative Binding*
Gly-Leu-Phe-Glu-Asp	7	100
Gly-Phe-Phe-Glu-Asp	17	200
Gly-Trp-Phe-Glu-Asp	18	343
Gly-Tyr-Phe-Glu-Asp	19	220
Gly-Leu-Trp-Glu-Asp	20	207
Gly-Leu-Phe-Cys-Asp	21	335
Gly-Leu-Phe-Asp-Asp	22	121
Gly-Leu-Phe-Phe-Asp	23	184
Gly-Leu-Phe-Ile-Asp	24	169
Gly-Leu-Phe-Leu-Asp	25	138
Gly-Leu-Phe-Trp-Asp	26	578
Gly-Leu-Phe-Tyr-Asp	27	252
Gly-Leu-Phe-Glu-Cys	28	296
Gly-Leu-Phe-Glu-Phe	29	204
Gly-Leu-Phe-Glu-Ile	30	174
Gly-Leu-Phe-Glu-Leu	31	168
Gly-Leu-Phe-Glu-Val	32	177
Gly-Leu-Phe-Glu-Trp	33	594
Gly-Leu-Phe-Glu-Tyr	34	386

10

\* Relative Binding of MAb4155 to peptides as measured by ELISA as described above

15 *D-isomers of the Reverse Sequence of the Core Binding Regions.*

The foregoing SEQ ID NO.'s 1-34 are L-isomers. It was also demonstrated that the D-isomers of the reverse sequences of those core binding regions identified above similarly function as effective mimotopes. For example, an amino acid sequence as described by SEQ ID NO:36 was prepared by the peptide synthesis methods described above. Binding affinity relative to the parent

20

- 23 -

sequence (SEQ ID NO:27) was measured by the described testing methods. The results show the reverse sequence to have an equivalent relative binding affinity compared to the parent sequence.

5

The following therefore identify core binding sequences of peptides capable of functioning as mimotopes for estradiol. Each sequence contains D-isomers of the amino acids in the reverse sequence of one of those described above.

10

Asp-Glu-Phe (SEQ ID NO:35)

Asp-Tyr-Phe-Leu-Gly (SEQ ID NO:36)

Asp-Glu-Phe-Phe-Gly (SEQ ID NO:37)

Asp-Glu-Phe-Trp-Gly (SEQ ID NO:38)

15 

Asp-Glu-Phe-Tyr-Gly (SEQ ID NO:39)

Asp-Glu-Trp-Leu-Gly (SEQ ID NO:40)

Asp-Cys-Phe-Leu-Gly (SEQ ID NO:41)

Asp-Asp-Phe-Leu-Gly (SEQ ID NO:42)

Asp-Phe-Phe-Leu-Gly (SEQ ID NO:43)

20 

Asp-Ile-Phe-Leu-Gly (SEQ ID NO:44)

Asp-Leu-Phe-Leu-Gly (SEQ ID NO:45)

Asp-Trp-Phe-Leu-Gly (SEQ ID NO:46)

Cys-Glu-Phe-Leu-Gly (SEQ ID NO:47)

Phe-Glu-Phe-Leu-Gly (SEQ ID NO:48)

25 

Ile-Glu-Phe-Leu-Gly (SEQ ID NO:49)

Leu-Glu-Phe-Leu-Gly (SEQ ID NO:50)

Val-Glu-Phe-Leu-Gly (SEQ ID NO:51)

Trp-Glu-Phe-Leu-Gly (SEQ ID NO:52)

Tyr-Glu-Phe-Leu-Gly (SEQ ID NO:53)

30 

Phe-Gly-Leu-Val-Tyr-Thr-Trp-Ala-Thr (SEQ ID NO:54)

Pro-Gly-Leu-Val-Tyr-Ala-Trp-Ser-Thr (SEQ ID NO:55)

- 24 -

**EXAMPLE 2****Identification of Peptide Mimotope Sequences from Pepscan Libraries**

5 The pins from the Multipin Peptide Synthesis Kit as described in  
 Example 1 were used to construct libraries of peptide sequences  
 encompassing all possible trimer combinations of the 20 naturally  
 occurring amino acids, supplemented by a further random set of  
 10 dodecapeptides (Slootstra JW et al., *Screening of a small set of  
 random peptides: a new strategy to identify synthetic peptides that  
 mimic epitopes* J Molec. Recog. 10, 217-224 (1997)). The binding  
 of MAb4155 was tested on the library for binding affinity in a  
 manner as described in Example 1. This identified the following  
 amino acid sequences (L-isomers) as core binding regions for  
 15 estradiol mimotopes.

	Asp-Phe-Tyr	(SEQ ID NO:56)
	Phe-Tyr-Glu	(SEQ ID NO:57)
	Tyr-Glu-Glu	(SEQ ID NO:58)
20	Tyr-Gln-Glu	(SEQ ID NO:59)
	Asn-Glu-Glu-Asp-Phe-Tyr-Gln-Ile-Gln-Leu-Tyr-Glu	(SEQ ID NO:60)
	Arg-Gln-Ile-Asp-Phe-Tyr-Gln-Glu-Ile-Gln-Phe-Lys	(SEQ ID NO:61)
	Asp-Asp-Phe-Tyr-Gly-Gln-Pro-Arg-Glu-Gln-Val-Arg	(SEQ ID NO:62)

25 Similarly to Example 1 the following reverse sequences of D-amino  
 acids are identified as capable of functioning as the core binding  
 region for peptide mimotopes for estradiol.

	Tyr-Phe-Asp	(SEQ ID NO:63)
30	Glu-Tyr-Phe	(SEQ ID NO:64)
	Glu-Glu-Tyr	(SEQ ID NO:65)
	Glu-Gln-Tyr	(SEQ ID NO:66)
	Glu-Tyr-Leu-Gln-Ile-Gln-Tyr-Phe-Asp-Glu-Glu-Asn	(SEQ ID NO:67)
	Lys-Phe-Gln-Ile-Glu-Gln-Tyr-Phe-Asp-Ile-Gln-Arg	(SEQ ID NO:68)

- 25 -

Arg-Val-Gln-Glu-Arg-Pro-Gln-Gly-Tyr-Phe-Asp-Asp (SEQ ID NO:69)

**EXAMPLE 3**

**Comparison of Competitive Assays for Estrone-3-Glucuronide (E3G)**

5 **Using E3G or a Peptide Mimotope of E3G on a Solid Phase**

Peptide Ligand Synthesis

10 Synthetic peptide ligands were prepared on an Applied Biosystems 431A Peptide Synthesiser Biopolymer Synthesis and Analysis Unit, TM QMC, (Nottingham, UK). Purity was assessed by mass spectroscopy and HPLC and was in excess of 95%.

Preparation of Ovalbumin-E3G conjugate

15 An estrone-3-glucuronide (E3G) ovalbumin conjugate was prepared by resuspending 2.6mg of E3G in 2ml of freshly prepared solution of EDC (1-ethyl (dimethylaminopropyl) carbodiimide, 0.1M) and NHS (N-hydroxysuccinamide, 0.02M) and incubating for 15minutes at room  
20 temperature. To the E3G solution, 2ml of ovalbumin (10mg/ml) was added and this was incubated for 2.5hrs at room temperature with constant mixing. The conjugate was then dialysed for 16hrs against 1L of phosphate buffered saline containing 0.1% sodium azide.

25 Preparation of BSA- mimotope conjugate

Bovine serum albumin (BSA, 10mg, Sigma) was dissolved in 3 ml of conjugation buffer (sodium hydrogen carbonate buffer, 0.1M, pH 8.4) in a clean glass vial, mixing by suction and expulsion from a  
30 pipette tip. The mixture was left on a roller for one hour. The peptide mimotope as represented by SEQ ID NO:36 was dissolved in conjugation buffer. Peptide solution (1.0 ml @ 10mg/ml) and 10µl glutaraldehyde (high commercial grade, Sigma) were added to the BSA solution. The sealed vial was then agitated on a roller for four

- 26 -

hours at room temperature. The conjugate solution was then dialysed against sodium chloride (0.9%w/v) for 48h at 4°C.

#### Assays:

- 5 Peptide-mimotope-BSA conjugate (10µg/ml) and E3G-ovalbumin conjugate (3µg/ml) were dried separately into the wells of a microtitre plate (Becton Dickinson, CA, USA) from 50µl of solution in Phosphate Buffered Saline (PBS) overnight at room temperature. Wells were washed (4x PBS+0.01%Tween20™), blocked for 1 hour with
- 10 0.1% casein in 100µl of PBS and washed 4x before use. 25µl aliquots of E3G in PBS (0-3µM) were added and incubated for 15mins before adding in 25µl of the MAb4155 anti-E3G antibody at 0.6µg/ml in PBS. The wells were incubated, with agitation, for 1 hour at room temperature. After washing 4x, 50µl of rabbit anti-mouse IgG-
- 15 HRP conjugate (Dako, High Wycombe, UK) at 1:1000 dilution in PBS was added to each well and incubated for 1 hour at room temperature. After washing 4x, the wells were incubated in ABTS [2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)] working substrate for 15 min (150 µl/well). ABTS was prepared as a 0.033% (w/v) solution in 0.1M citrate phosphate buffer (pH 4.5) with 33% hydrogen peroxide (1 µl/ml). Colour development was terminated by addition of 0.5M sulphuric acid (10µl/well) and was measured spectrophotometrically at 405 nm using a Milenia Kinetic Analyser™ (DPC, Llanberis, Wales).

25

- Figure 1 shows the resulting assay curves. Both are typical for competitive immunoassays having midpoints in the micromolar to nanomolar range. Furthermore, the assay sensitivity using the mimotope-containing BSA-SEQ ID NO:36 is significantly greater than
- 30 that obtained when using the epitope-containing E3G-ovalbumin.

The invention has been described in detail with particular reference to preferred embodiments thereof, but it will be

- 27 -

understood that variations and modifications can be effected with the spirit and scope of the invention.





- 28 -

Claims:

What is claimed is:

- 5 1. A purified peptide mimotope which is capable of binding specifically to an antibody specific to estradiol.
2. A purified peptide mimotope which is capable of binding specifically to an antibody specific to estradiol, wherein the  
10 mimotope has a core binding region of no greater than 12 amino acid residues.
3. A purified peptide mimotope according to claim 1 having a core binding region represented by an amino acid sequence selected  
15 from the group consisting of SEQ ID NO's: 3-5 and 17-69.
4. A purified peptide mimotope according to any of the preceding claims which is capable of binding specifically to an antibody specific to estrone-3-glucorinide.  
20
5. A purified peptide mimotope according to any of the preceding claims comprising an amino acid sequence selected from the group consisting of SEQ ID NO's: 6-16.
- 25 6. An immunoassay test device for the detection in a sample of estradiol, the immunoassay comprising a peptide mimotope according to any of the preceding claims, and an antibody capable of binding specifically to the peptide mimotope to generate a detectable signal.  
30
7. An immunoassay test device according to claim 6 wherein the test device is a competitive immunoassay test device.

- 29 -

8. An immunoassay test device according to any of claims 6 or 7 wherein the peptide mimotope comprises an amino acid sequence having a core binding region selected from the group consisting of SEQ ID NO's: 3-5 and 17-69.

5

9. An immunoassay test device according to any of claims 6 to 8 wherein the peptide mimotope comprises an amino acid sequence selected from the group consisting of SEQ ID NO's: 6-16.

10 10. An immunoassay test device according to any of claims 6 to 9 wherein the peptide mimotope is capable of binding specifically to an antibody specific to estrone-3-glucuronide.

15 11. Use of a peptide according to any of claims 1 to 5 as a mimotope to probe for the presence of estradiol in a sample to be tested.

- 30 -

**Abstract**


A purified peptide mimotope which is capable of binding specifically to an antibody specific to estradiol. Also disclosed  
5 is an immunoassay test device for the detection in a sample of estradiol, the immunoassay test device comprising a peptide mimotope of estradiol, and an antibody capable of binding specifically to the peptide mimotope to generate a detectable  
10 signal.

10



- 31 -

Figure 1





- 1/19 -

## SEQUENCE LISTING

<110> UNILEVER PLC

5 <120> Peptides Capable of Functioning as Mimotopes for  
Hormonal Analytes

<130> P3111

10 <140>  
<141>

<160> 80

15 <170> PatentIn Ver. 2.1

<210> 1  
<211> 19  
<212> DNA

20 <213> Unknown Organism

<220>  
<223> Description of Unknown Organism:Oligonucleotide  
Primer

25 <400> 1  
tttcccagtc acgacgttg

30 <210> 2  
<211> 9  
<212> PRT  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 2  
Ala Ala Glu Arg Gly Leu Phe Glu Asp

40 1 5

<210> 3  
<211> 9

45 <212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

50 <400> 3  
Thr Ala Trp Thr Tyr Val Leu Gly Phe

1 5

55 <210> 4  
<211> 9  
<212> PRT

19

- 2/19 -

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

5 <400> 4  
Thr Ser Trp Ala Tyr Val Leu Gly Pro  
1 5

10 <210> 5  
<211> 3  
<212> PRT  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence:Mimotope

20 <400> 5  
Phe Glu Asp  
1

25 <210> 6  
<211> 4  
<212> PRT  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence:Mimotope

35 <400> 6  
Leu Phe Glu Asp  
1

40 <210> 7  
<211> 5  
<212> PRT  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence:Mimotope

50 <400> 7  
Gly Leu Phe Glu Asp  
1 5

55 <210> 8  
<211> 6  
<212> PRT  
<213> Artificial Sequence

55 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 8



- 3/19 -

Arg Gly Leu Phe Glu Asp  
1 5

5 <210> 9  
<211> 7  
<212> PRT  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 9  
Glu Arg Gly Leu Phe Glu Asp  
15 1 5

<210> 10  
<211> 8  
20 <212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

25 <400> 10  
Ala Glu Arg Gly Leu Phe Glu Asp  
1 5

30 <210> 11  
<211> 9  
<212> PRT  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 11  
40 Gly Ala Glu Arg Gly Leu Phe Glu Asp  
1 5

<210> 12  
45 <211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
50 <223> Description of Artificial Sequence:Mimotope

<400> 12  
Ala Gly Glu Arg Gly Leu Phe Glu Asp  
1 5

55 <210> 13  
<211> 9

- 4/19 -

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

5 &lt;223&gt; Description of Artificial Sequence:Mimotope

&lt;400&gt; 13

Ala Ala Ala Arg Gly Leu Phe Glu Asp

1

5

10

&lt;210&gt; 14

&lt;211&gt; 9

&lt;212&gt; PRT

15 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

20 &lt;400&gt; 14

Ala Ala Glu Ala Gly Leu Phe Glu Asp

1

5

25 &lt;210&gt; 15

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

30 &lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

&lt;400&gt; 15

Ala Ala Glu Arg Ala Leu Phe Glu Asp

1

5

35

&lt;210&gt; 16

&lt;211&gt; 9

&lt;212&gt; PRT

40

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

45

&lt;400&gt; 16

Ala Ala Glu Arg Gly Ala Phe Glu Asp

1

5

50

&lt;210&gt; 17

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

55

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

- 5/19 -

<400> 17  
Gly Phe Phe Glu Asp  
1 5

5

<210> 18  
<211> 5  
<212> PRT  
<213> Artificial Sequence

10

<220>  
<223> Description of Artificial Sequence:Mimotope

<400> 18  
15 Gly Trp Phe Glu Asp  
1 5

20

<210> 19  
<211> 5  
<212> PRT  
<213> Artificial Sequence

25

<220>  
<223> Description of Artificial Sequence:Mimotope

<400> 19  
Gly Tyr Phe Glu Asp  
1 5

30

<210> 20  
<211> 5  
<212> PRT  
35 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

40

<400> 20  
Gly Leu Trp Glu Asp  
1 5

45

<210> 21  
<211> 5  
<212> PRT  
<213> Artificial Sequence

50

<220>  
<223> Description of Artificial Sequence:Mimotope

<400> 21  
55 Gly Leu Phe Cys Asp  
1 5

<210> 22

- 6/19 -

<211> 5  
<212> PRT  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 22  
Gly Leu Phe Asp Asp  
10 1 5

<210> 23  
<211> 5  
15 <212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

20 <400> 23  
Gly Leu Phe Phe Asp  
1 5

25 <210> 24  
<211> 5  
<212> PRT  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 24  
35 Gly Leu Phe Ile Asp  
1 5

40 <210> 25  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
45 <223> Description of Artificial Sequence:Mimotope

<400> 25  
Gly Leu Phe Leu Asp  
1 5

50 <210> 26  
<211> 5  
<212> PRT  
55 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

- 7/19 -

5       <400> 26  
      Gly Leu Phe Trp Asp  
          1                   5

10       <210> 27  
          <211> 5  
          <212> PRT  
          <213> Artificial Sequence

15       <220>  
          <223> Description of Artificial Sequence:Mimotope

20       <400> 27  
      Gly Leu Phe Tyr Asp  
          1                   5

25       <210> 28  
          <211> 5  
          <212> PRT  
          <213> Artificial Sequence

30       <220>  
          <223> Description of Artificial Sequence:Mimotope

      <400> 28  
      Gly Leu Phe Glu Cys  
          1                   5

35       <210> 29  
          <211> 5  
          <212> PRT  
          <213> Artificial Sequence

40       <220>  
          <223> Description of Artificial Sequence:Mimotope

45       <400> 29  
      Gly Leu Phe Glu Phe  
          1                   5

50       <210> 30  
          <211> 5  
          <212> PRT  
          <213> Artificial Sequence

55       <220>  
          <223> Description of Artificial Sequence:Mimotope

      <400> 30  
      Gly Leu Phe Glu Ile  
          1                   5

- 8/19 -

5      <210> 31  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
      <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
10     <400> 31  
      Gly Leu Phe Glu Leu  
        1                    5  
  
15     <210> 32  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
      <220>  
20     <223> Description of Artificial Sequence:Mimotope  
  
      <400> 32  
      Gly Leu Phe Glu Val  
        1                    5  
25  
  
      <210> 33  
      <211> 5  
      <212> PRT  
30     <213> Artificial Sequence  
  
      <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
35     <400> 33  
      Gly Leu Phe Glu Trp  
        1                    5  
  
40     <210> 34  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
45     <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
      <400> 34  
      Gly Leu Phe Glu Tyr  
50     1                    5  
  
      <210> 35  
      <211> 3  
55     <212> PRT  
      <213> Artificial Sequence  
  
      <220>

- 9/19 -

<223> Description of Artificial Sequence:Mimotope

<400> 35  
Asp Glu Phe  
5 1

<210> 36  
<211> 5  
10 <212> PRT  
<213> Artificial Sequence

<220>  
15 <223> Description of Artificial Sequence:Mimotope

<400> 36  
Asp Tyr Phe Leu Gly  
1 5

20 <210> 37  
<211> 5  
<212> PRT  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 37  
30 Asp Glu Phe Phe Gly  
1 5

35 <210> 38  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
40 <223> Description of Artificial Sequence:Mimotope

<400> 38  
Asp Glu Phe Trp Gly  
1 5

45 <210> 39  
<211> 5  
<212> PRT  
50 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

55 <400> 39  
Asp Glu Phe Tyr Gly  
1 5

- 10/19 -

5     <210> 40  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
      <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
10    <400> 40  
      Asp Cys Phe Leu Gly  
          1                  5  
  
15    <210> 41  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
20    <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
      <400> 41  
      Asp Asp Phe Leu Gly  
25       1                  5  
  
30    <210> 42  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
      <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
35    <400> 42  
      Asp Phe Phe Leu Gly  
          1                  5  
  
40    <210> 43  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence  
  
45    <220>  
      <223> Description of Artificial Sequence:Mimotope  
  
      <400> 43  
50    Asp Ile Phe Leu Gly  
          1                  5  
  
55    <210> 44  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence



- 11/19 -

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

&lt;400&gt; 44

5 Asp Leu Phe Leu Gly  
1 5

&lt;210&gt; 45

10 &lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

15 &lt;223&gt; Description of Artificial Sequence:Mimotope

&lt;400&gt; 45

Asp Trp Phe Leu Gly  
1 5

20

&lt;210&gt; 46

&lt;211&gt; 5

&lt;212&gt; PRT

25 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

30 &lt;400&gt; 46

Cys Glu Phe Leu Gly  
1 5

35 &lt;210&gt; 47

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

40 &lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Mimotope

&lt;400&gt; 47

45 Phe Glu Phe Leu Gly  
1 5

&lt;210&gt; 48

&lt;211&gt; 5

50 &lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

55 &lt;223&gt; Description of Artificial Sequence:Mimotope

&lt;400&gt; 48

Ile Glu Phe Leu Gly  
1 5

- 12/19 -

5      <210> 49  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence

10     <220>  
      <223> Description of Artificial Sequence:Mimotope

      <400> 49  
      Leu Glu Phe Leu Gly  
          1                   5

15     <210> 50  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence

20     <220>  
      <223> Description of Artificial Sequence:Mimotope

25     <400> 50  
      Val Glu Phe Leu Gly  
          1                   5

30     <210> 51  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence

35     <220>  
      <223> Description of Artificial Sequence:Mimotope

40     <400> 51  
      Trp Glu Phe Leu Gly  
          1                   5

45     <210> 52  
      <211> 5  
      <212> PRT  
      <213> Artificial Sequence

50     <220>  
      <223> Description of Artificial Sequence:Mimotope

      <400> 52  
      Tyr Glu Phe Leu Gly  
          1                   5

55     <210> 53  
      <211> 9  
      <212> PRT  
      <213> Artificial Sequence

- 13/19 -

<220>  
<223> Description of Artificial Sequence:Mimotope

5   <400> 53  
    Phe Gly Leu Val Tyr Thr Trp Ala Thr  
      1                                  5

10   <210> 54  
      <211> 9  
      <212> PRT  
      <213> Artificial Sequence

15   <220>  
      <223> Description of Artificial Sequence:Mimotope

      <400> 54  
      Pro Gly Leu Val Tyr Ala Trp Ser Thr  
20       1                                  5

      <210> 55  
      <211> 3  
25   <212> PRT  
      <213> Artificial Sequence

      <220>  
      <223> Description of Artificial Sequence:Mimotope

30   <400> 55  
      Asp Phe Tyr  
      1

35   <210> 56  
      <211> 3  
      <212> PRT  
      <213> Artificial Sequence

40   <220>  
      <223> Description of Artificial Sequence:Mimotope

      <400> 56  
45   Phe Tyr Glu  
      1

50   <210> 57  
      <211> 3  
      <212> PRT  
      <213> Artificial Sequence

55   <220>  
      <223> Description of Artificial Sequence:Mimotope

      <400> 57  
      Tyr Glu Glu

- 14/19 -

```

1
5  <210> 58
   <211> 3
   <212> PRT
   <213> Artificial Sequence
10 <220>
   <223> Description of Artificial Sequence:Mimotope
   <400> 58
   Tyr Gln Glu
       1
15
   <210> 59
   <211> 12
   <212> PRT
20 <213> Artificial Sequence
   <220>
   <223> Description of Artificial Sequence:Mimotope
25 <400> 59
   Asn Glu Glu Asp Phe Tyr Gln Ile Gln Leu Tyr Glu
       1             5             10
30 <210> 60
   <211> 12
   <212> PRT
   <213> Artificial Sequence
35 <220>
   <223> Description of Artificial Sequence:Mimotope
   <400> 60
   Arg Gln Ile Asp Phe Tyr Gln Glu Ile Gln Phe Lys
40       1             5             10
   <210> 61
   <211> 12
45 <212> PRT
   <213> Artificial Sequence
   <220>
   <223> Description of Artificial Sequence:Mimotope
50 <400> 61
   Asp Asp Phe Tyr Gly Gln Pro Arg Glu Gln Val Arg
       1             5             10
55 <210> 62
   <211> 3
   <212> PRT

```

- 15/19 -

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

5 <400> 62  
Tyr Phe Asp  
1

10 <210> 63  
<211> 3  
<212> PRT  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence:Mimotope

20 <400> 63  
Glu Tyr Phe  
1

25 <210> 64  
<211> 3  
<212> PRT  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 64  
Glu Glu Tyr  
1

35 <210> 65  
<211> 3  
<212> PRT

40 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

45 <400> 65  
Glu Gln Tyr  
1

50 <210> 66  
<211> 12  
<212> PRT  
<213> Artificial Sequence

55 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 66

- 16/19 -

Glu Tyr Leu Gln Ile Gln Tyr Phe Asp Glu Glu Asn  
 1 5 10

5 <210> 67  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

10 <220>  
 <223> Description of Artificial Sequence:Mimotope

<400> 67

Lys Phe Gln Ile Glu Gln Tyr Phe Asp Ile Gln Arg  
 15 1 5 10

20 <210> 68  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Mimotope

<400> 68

Arg Val Gln Glu Arg Pro Gln Gly Tyr Phe Asp Asp  
 25 1 5 10

30 <210> 69  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

35 <220>  
 <223> Description of Artificial Sequence:Mimotope

<400> 69

Arg Val Gln Glu Arg Pro Gln Gly Tyr Phe Asp Asp  
 40 1 5 10

45 <210> 70  
 <211> 2  
 <212> PRT  
 <213> Artificial Sequence

50 <220>  
 <223> Description of Artificial Sequence:Mimotope

<400> 70

Glu Asp  
 1

55 <210> 71  
 <211> 8

- 17/19 -

<212> PRT  
<213> Artificial Sequence

<220>  
5 <223> Description of Artificial Sequence:Mimotope

<400> 71  
Ala Ala Glu Arg Gly Leu Phe Glu  
1 5

10

<210> 72  
<211> 7  
<212> PRT  
15 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

20 <400> 72  
Ala Ala Glu Arg Gly Leu Phe  
1 5

25 <210> 73  
<211> 6  
<212> PRT  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 73  
Ala Ala Glu Arg Gly Leu  
35 1 5

<210> 74  
<211> 5  
40 <212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

45 <400> 74  
Ala Ala Glu Arg Gly  
1 5

50 <210> 75  
<211> 4  
<212> PRT  
<213> Artificial Sequence

55 <220>  
<223> Description of Artificial Sequence:Mimotope

- 18/19 -

<400> 75  
Ala Ala Glu Arg  
1

5

<210> 76  
<211> 3  
<212> PRT  
<213> Artificial Sequence

10

<220>  
<223> Description of Artificial Sequence:Mimotope

<400> 76  
15 Ala Ala Glu  
1

<210> 77  
20 <211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
25 <223> Description of Artificial Sequence:Mimotope

<400> 77  
Ala Ala  
1

30

<210> 78  
<211> 9  
<212> PRT  
35 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Mimotope

40 <400> 78  
Ala Ala Glu Arg Gly Leu Ala Glu Asp  
1 5

45 <210> 79  
<211> 9  
<212> PRT  
<213> Artificial Sequence

50 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 79  
Ala Ala Glu Arg Gly Leu Phe Ala Asp  
55 1 5

<210> 80



- 19/19 -

<211> 9  
<212> PRT  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence:Mimotope

<400> 80  
Ala Ala Glu Arg Gly Leu Phe Glu Ala  
10       1                       5

